15(R)-Lipoxin A4 – 100 µg

Brand:
Cayman
CAS:
171030-11-8
Storage:
-80
UN-No:
De Minimis - 1170 / 3

Lipid-derived lipoxins are produced at the site of vascular and mucosal inflammation where they down-regulate polymorphonuclear leukocyte recruitment and function. 15(R)-Lipoxin A4 (15(R)-LXA4) is derived from the aspirin-triggered formation of 15(R)-HETE (Item No. 34710) from arachidonic acid (Item No. 90010).{3520,2629} 15(R)-LXA4 inhibits LTB4-induced chemotaxis, adherence, and transmigration of neutrophils with twice the potency of LXA4 (Item No. 90410) demonstrating activity in the nM range.{2629,11078} The anti-inflammatory effects of aspirin may be ascribed in part to the ability of 15(R)-LXA4 to regulate leukocyte function.{15182} 15(R)-LXA4 is reported to promote resolution of inflammation in LPS-treated stromal cells derived from intermediate-stage diseased supraspinatus tendons as evidenced by increased expression of the STAT-6 pathway target genes, ALOX15 and CD206.{29947}  

 

Available on backorder

SKU: 90415 - 100 µg Category:

Description

An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adherence, and transmigration of the neutrophils with twice the potency of LXA4 demonstrating activity in the nM range


Formal name: 5(S),6(R),15(R)-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid

Synonyms:  15(R)-LXA4|15-epi Lipoxin A4|AT-Lipoxin A4

Molecular weight: 352.5

CAS: 171030-11-8

Purity: ≥95%

Formulation: A solution in ethanol